Biohaven (BHVN) Retained Earnings (2022 - 2026)
Biohaven (BHVN) posted Retained Earnings of -$2.2 billion for Q1 2026, down 1241.88% sequentially from $194.0 million in Q4 2025, and down 41.32% YoY from -$3.8 billion in Q1 2025.
Analysis
Biohaven (BHVN) Retained Earnings (2022 - 2026) Analysis & Trends
Biohaven has reported Retained Earnings for 5 years, with the latest figure at -$2.2 billion in Q1 2026.
- Quarterly Retained Earnings fell 41.32% year-over-year to -$2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.2 billion (down 41.32% YoY) and the FY2025 annual result came in at $194.0 million, up 114.41% from the prior year.
- Retained Earnings slipped to -$2.2 billion in Q1 2026 per BHVN's latest filing, from $194.0 million in the prior quarter.
- Over five years, Retained Earnings peaked at $194.0 million in Q4 2025 and troughed at -$2.2 billion in Q1 2026.
- A 5-year average of -$520.4 million and a median of $101000.0 in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings slumped 175907.04% in 2023, then soared 41698.19% in 2024.
- Over 5 years, Retained Earnings stood at $284000.0 in 2022, then plunged by 175907.04% to -$499.3 million in 2023, then slumped by 169.52% to -$1.3 billion in 2024, then surged by 114.41% to $194.0 million in 2025, then slumped by 1241.88% to -$2.2 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$2.2 billion, $194.0 million, and $36000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Biohaven | 2.37 Bn | 2.10 Bn | - | -2.35 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.35 Bn |
| Mar 31, 2026 | -2.22 Bn |
| Dec 31, 2025 | -2.08 Bn |
| Sep 30, 2025 | -1.94 Bn |
| Jun 30, 2025 | -1.77 Bn |
| Mar 31, 2025 | -1.57 Bn |
| Dec 31, 2024 | -1.35 Bn |
| Sep 30, 2024 | -1.16 Bn |
| Jun 30, 2024 | -998.57 Mn |
| Mar 31, 2024 | -678.80 Mn |
| Dec 31, 2023 | -499.29 Mn |
| Sep 30, 2023 | -354.54 Mn |
| Jun 30, 2023 | -251.96 Mn |
| Mar 31, 2023 | -161.62 Mn |
| Dec 31, 2022 | -91.12 Mn |